In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis: Bartering for Growth

Executive Summary

This genomics-based company has used business development as a strategic tool, swapping for key capacities that have helped it quickly leap forward. As the company demonstrated the merits of its model-organism platform, it began asking partners not for the most money they would give--but for assets that would help it forward integrate. One deal that started small expanded into a life-changing technology swap: from BMS, Exelixis got combinatorial chemistry capacity that it can now use to make compounds against its own targets. It also got a Phase II drug candidate for cancer, and rights to half of the molecules it makes for BMS, and Exelixis has used its new chemistry capacity to sign other barter-driven deals. Rapid evolution has risks: unless Exelixis accesses other fairly mature drug candidates, there will be a gap between launch of its first product and other compounds that haven't been tried yet in humans.
Advertisement

Related Content

Deals Of The Week: Exelixis/BMS, Valeant/Dow, Novartis Option Fund/Ascent
Exelixis Cashes In on Discovery
Exelixis Cashes In on Discovery
Exelixis/GSK: Using Project Financing to Accelerate R&D
The Cooperative, Competitive Future of Pharma R&D
GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer
GSK/Exelixis and In-Licensing: Earlier, Richer, Rarer
Why Pharma Needs to Do Early-Stage Deals
Why Pharma Needs to Do Early-Stage Deals
Selling Structure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel